Early risk assessment in paediatric and adult household contacts of confirmed tuberculosis cases by novel diagnostic tests (ERASE-TB): protocol for a prospective, non-interventional, longitudinal, multicountry cohort study
,
Ursula Panzner,
Katharina Kranzer,
Tsitsi Bandason,
Kuda Mutasa,
Sandra Rukobo,
Charles Sandy,
Bariki Mtafya,
Andrea Rachow,
Norbert Heinrich,
Michael Hoelscher,
Judith Bruchfeld,
Olena Ivanova,
Nyanda Elias Ntinginya,
Doreen Pamba,
Laura Olbrich,
Issa Sabi,
Simeon Mwanyonga,
Elmar Saathoff,
Willyhelmina Olomi,
Junior Mutsvangwa,
Hazel M Dockrell,
Edson Tawanda Marambire,
Denise Banze,
Alfred Mfinanga,
Theodora D Mbunda,
Khosa Celso,
Gunilla Kallenius,
Claire J Calderwood,
Christof Geldmacher,
Kathrin Held,
Tejaswi Appalarowthu,
Friedrich Rieß,
Anna Shepherd,
Christopher Sundling,
Mishelle Mugava,
Martha Chipinduro,
Lwitiho Sudi,
Antelmo Haule,
Emmanuel Sichone,
Paschal Qwaray,
Harrieth Mwambola,
Lilian Minja,
Peter Edwin,
Dogo Ngalison,
Stella Luswema,
Celina Nhamuave,
António Machiana,
Carla Madeira,
Emelva Manhiça,
Nádia Sitoe,
Jorge Ribeiro
Affiliations
Spanish Consortium for Genetics of Celiac Disease – Spanish Celiac Disease Society (SEEC), Spain
Ursula Panzner
Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany
Katharina Kranzer
1 Biomedical Research and Training Institute, Harare, Zimbabwe
Tsitsi Bandason
Kuda Mutasa
3 Research Team, Zvitambo Institute for Maternal and Child Health Research, Harare, Zimbabwe
Sandra Rukobo
Charles Sandy
Bariki Mtafya
Andrea Rachow
Norbert Heinrich
Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany
Michael Hoelscher
Judith Bruchfeld
Department of Infectious Disease, Karolinska University Hospital, Stockholm, Sweden
Olena Ivanova
Nyanda Elias Ntinginya
Department of Medicine, NIMR-Mbeya Medical Research Programme, Mbeya, Mbeya, Tanzania
Doreen Pamba
Laura Olbrich
Issa Sabi
Department of Paediatrics and Child Health, NIMR-Mbeya Medical Research Programme, Mbeya, Tanzania
Simeon Mwanyonga
Elmar Saathoff
Willyhelmina Olomi
2NIMR Mbeya Medical Research Centre, Tanzania
Junior Mutsvangwa
Biomedical Research and Training Institute, Harare, Zimbabwe
Hazel M Dockrell
Edson Tawanda Marambire
Biomedical Research and Training Institute, Harare, Zimbabwe
Denise Banze
Instituto Nacional de Saúde, Marracuene, Mozambique
Alfred Mfinanga
National Institute for Medical Research- Mbeya Medical Research Centre, Mbeya, Tanzania
Theodora D Mbunda
Department of Medicine, NIMR-Mbeya Medical Research Programme, Mbeya, Mbeya, Tanzania
Khosa Celso
Instituto Nacional de Saúde, Marracuene, Mozambique
Gunilla Kallenius
Karolinska Institutet, Stockholm, Sweden
Claire J Calderwood
Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK
Christof Geldmacher
Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany
Kathrin Held
Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany
Tejaswi Appalarowthu
Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany
Friedrich Rieß
German Center for Infection Research (DZIF), Partner site Munich, Munich, Germany
Anna Shepherd
Christopher Sundling
Mishelle Mugava
Martha Chipinduro
Lwitiho Sudi
Antelmo Haule
Emmanuel Sichone
Paschal Qwaray
Harrieth Mwambola
Lilian Minja
Peter Edwin
Dogo Ngalison
Stella Luswema
Celina Nhamuave
António Machiana
Carla Madeira
Emelva Manhiça
Nádia Sitoe
Jorge Ribeiro
Centro de Investigação e Treino em Saúde da Polana Caniço, Instituto Nacional de Saúde, Maputo, Mozambique
Introduction The WHO End-TB Strategy calls for the development of novel diagnostics to detect tuberculosis (TB) earlier and more accurately. Better diagnostics, together with tools to predict disease progression, are critical for achieving WHO End-TB targets. The Early Risk Assessment in TB Contacts by new diagnoStic tEsts (ERASE-TB) study aims to evaluate novel diagnostics and testing algorithms for early TB diagnosis and accurate prediction of disease progression among household contacts (HHCs) exposed to confirmed index cases in Mozambique, Tanzania and Zimbabwe.Methods and analysis A total of 2100 HHCs (aged ≥10 years) of adults with microbiologically-confirmed pulmonary TB will be recruited and followed up at 6-month intervals for 18–24 months. At each time point, a WHO symptom screen and digital chest radiograph (dCXR) will be performed, and blood and urine samples will be collected. Individuals screening positive (WHO symptom screen or dCXR) will be requested to provide sputum for Xpert MTB/Rif Ultra. At baseline, HHCs will also be screened for HIV, diabetes (HbA1c), chronic lung disease (spirometry), hypertension and anaemia. Study outcomes will be coprevalent TB (diagnosed at enrolment), incident TB (diagnosed during follow-up) or no TB at completion of follow-up. Novel diagnostics will be validated using fresh and biobanked samples with a nested case–control design. Cases are defined as HHCs diagnosed with TB (for early diagnosis) or with incident TB (for prediction of progression) and will be matched by age, sex and country to HHCs who remain healthy (controls). Statistical analyses will include assessment of diagnostic accuracy by constructing receiver operating curves and calculation of sensitivity and specificity.Ethics and dissemination ERASE-TB has been approved by regulatory and ethical committees in each African country and by each partner organisation. Consent, with additional assent for participants <18 years, is voluntary. Attestation by impartial witnesses is sought in case of illiteracy. Confidentiality of participants is being maintained throughout. Study findings will be presented at scientific conferences and published in peer-reviewed international journals.Trial registration number NCT04781257.Cite Now